« Calling Bill and Melinda Gates! | Main | Mixed Messages »

April 24, 2006

Comments

lag2

(apologies if this was covered in WSJ) but the New England Journal has been kind enough to publish several studies, most recently, this one, on the lack of benefit (and sometimes detriment) of the addition of clopidogrel, i.e., plavix, to a cardiovascular prevention regimen.
http://content.nejm.org/cgi/content/short/354/16/1706

thanks for the good reminder of the susceptibility of physicians- and patients- to medical techonology/pharmaceutical marketing.

The comments to this entry are closed.